NEW YORK (GenomeWeb News) – AstraZeneca and Dako Denmark announced today that they will collaborate on developing companion diagnostics for multiple AstraZeneca oncology drug programs.

The firms said that the AstraZeneca drug candidates will be biologics and small molecule drugs that are in various stages of development. They did not name specific cancer targets, nor did they provide any financial details of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.